{"schema_version":"secwatch.filing_event.v1","accession":"0001731122-22-002078","form_type":"8-K","ticker":"AVXL","cik":"0001314052","company_name":"ANAVEX LIFE SCIENCES CORP.","filed_at":"2022-12-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.091466+00:00","generated_at":"2026-06-21T10:08:14.780673+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Anavex Life Sciences announces positive Phase 2b/3 trial results for ANAVEX2-73 in Alzheimer's disease","bullets":["Trial met primary endpoints ADAS-Cog and ADCS-ADL with statistically significant results (p=0.033 and p=0.0255).","Key secondary endpoint CDR-SB also met (p=0.040), showing 27% reduction in clinical decline.","Patients treated with ANAVEX2-73 were 84% more likely to have improved cognition vs placebo (Odds Ratio=1.84).","ANAVEX2-73 demonstrated 45% reduction in cognitive decline measured by ADAS-Cog compared to placebo.","Company plans to meet with regulatory authorities to discuss next steps for approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001731122-22-002078","json":"https://secwatch.observer/filing/0001731122-22-002078.json","markdown":"https://secwatch.observer/filing/0001731122-22-002078.md","text":"https://secwatch.observer/filing/0001731122-22-002078.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1314052/000173112222002078/0001731122-22-002078-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1314052/000173112222002078/e4271_8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T10:08:14.780673+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}